Up a level |
Lopes, G. and Wu, Y. and Kudaba, I. and Kowalski, D. and Cho, B. and Turna, H. and De Castro, G. and Srimuninnimit, V. and Laktionov, K. and Bondarenko, I. and Kubota, K. and Lubiniecki, G. and Zhang, J. and Kush, D. and Mok, T. (2018) PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%. Journal of Thoracic Oncology, Vol.13 (No. 9S). S152-S154. ISSN 1556-0864
Lopes, G. and Wu, Y. and Kudaba, I. and Kowalski, D. and Cho, B. and Turna, H. and De Castro, G. and Srimuninnimit, V. and Laktionov, K. and Bondarenko, I. and Kubota, K. and Lubiniecki, G. and Zhang, J. and Kush, D. and Mok, T. (2018) Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%. Journal of Thoracic Oncology, Vol.13 (No.9S). S152-S154.